Stage i Lung SBRT Clinical Practice Patterns

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 4, 2017, Pages 358-361

  Corso, Christopher D ^a   Park, Henry S ^a   Moreno, Amy C ^a   Kim, Anthony W ^b   Yu, James B ^a   Husain, Zain A ^a   Decker, Roy H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

BED; NCDB; NSCLC; SABR; SBRT

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRESCRIPTION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; UNITED STATES; CARCINOMA, NON-SMALL-CELL LUNG; FACTUAL DATABASE; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; RADIOSURGERY; RADIOTHERAPY DOSAGE; STATISTICS AND NUMERICAL DATA; TRENDS; UTILIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; HUMANS; LUNG NEOPLASMS; PRACTICE PATTERNS, PHYSICIANS'; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84916898134     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000162     Document Type: Article

References (17)

1. Pan H, Simpson DR, Mell LK, et al. A survey of stereotactic bodyradiotherapy use in the United States. Cancer. 2011;117:4566-4572.
2. Pan H, Rose BS, Simpson DR, et al. Clinical practice patterns oflung stereotactic body radiation therapy in the United States: Asecondary analysis. Am J Clin Oncol. 2013;36:269-272.
3. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionatedhigh-dose irradiation for stage I nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multiinstitutionalstudy. Cancer. 2004;101:1623-1631.
4. Grills IS, Hope AJ, Guckenberger M, et al. A collaborativeanalysis of stereotactic lung radiotherapy outcomes for early-stagenon-small-cell lung cancer using daily online cone-beam computedtomography image-guided radiotherapy. J Thorac Oncol. 2012;7:1382-1393.
5. Timmerman R, Paulus R, Galvin J, et al. Stereotactic bodyradiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076.
6. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of aphase I/II study of 48 Gy of stereotactic body radiotherapy in 4fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427-1431.
7. Senthi S, Haasbeek CJ, Slotman BJ, et al. Outcomes of stereotacticablative radiotherapy for central lung tumours: A systematicreview. Radiother Oncol. 2013;106:276-282.
8. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessivetoxicity when treating central tumors in a phase II study ofstereotactic body radiation therapy for medically inoperable earlystagelung cancer. J Clin Oncol. 2006;24:4833-4839.
9. Bilimoria KY, Stewart AK, Winchester DP, et al. The NationalCancer Data Base: A powerful initiative to improve cancer care inthe United States. Ann Surg Oncol. 2008;15:683-690.
10. National Cancer Database. [cited 2013 12/27]; Available at:http://ncdbpufbeta. facs. org/.
11. Rutter CE, Corso CD, Park HS, et al. Increase in the use of lungstereotactic body radiotherapy without a preceding biopsy in theUnited States. Lung Cancer. 2014;85:390-394.
12. Stephans KL, Djemil T, Tendulkar RD, et al. Prediction of chestwall toxicity from lung stereotactic body radiotherapy (SBRT). IntJ Radiat Oncol Biol Phys. 2012;82:974-980.
13. Li Q, Swanick CW, Allen PK, et al. Stereotactic ablativeradiotherapy (SABR) using 70Gy in 10 fractions for non-smallcell lung cancer: Exploration of clinical indications. RadiotherOncol. 2014;112:256-261.
14. Coroller TP, Mak RH, Lewis JH, et al. Low incidence of chestwall pain with a risk-adapted lung stereotactic body radiationtherapy approach using three or five fractions based on chest walldosimetry. PLoS One. 2014;9:e94859.
15. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotacticbody radiation therapy in Japan by the Japan 3-D ConformalExternal Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009;75:343-347.
16. Ohri N, Werner-Wasik M, Grills IS, et al. Modeling local control afterhypofractionated stereotactic body radiation therapy for stage I nonsmallcell lung cancer: A report from the elekta collaborative lungresearch group. Int J Radiat Oncol Biol Phys. 2012;84:e379-e384.
17. Cuaron JJ, Yorke ED, Foster A, et al. Stereotactic body radiationtherapy for primary lung cancers > 3 centimeters. J Thorac Oncol. 2013;8:1396-1401.